Additional Chikungunya Cases Reported in August 2024

Throughout 2024, chikungunya virus disease cases have been reported in the United States, primarily in international travelers returning from endemic areas in the Region of the Americas.

In the U.S., the Centers for Disease Control and Prevention (CDC) reported 52 travel-related cases this year.

As of August 2, 2024, the Pan American Health Organization (PAHO) reported 366,186 chikungunya cases. This data reflects a surge in cases compared with 411,000 for all of 2023.

From a prevention perspective, the CDC has issued recommendations for the only approved chikungunya vaccine.

In February 2024, the CDC's vaccine committee reviewed the protection offered by Valneva SE's IXCHIQ® vaccine. The CDC presented:

Short-term protection (28 days after vaccination) – 98% (611 of 622) combined seroresponse rate from two studies.

Long-term protection (12 months after vaccination) – 99% (356 of 360) seroresponse rate from one study.

IXCHIQ is available at select travel clinics and pharmacies in the U.S. and for adults in Canada and Europe.